These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 18978469)

  • 1. New approaches to treatment of primary immunodeficiencies: fixing mutations with chemicals.
    Hu H; Gatti RA
    Curr Opin Allergy Clin Immunol; 2008 Dec; 8(6):540-6. PubMed ID: 18978469
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Exon-skipping antisense oligonucleotides to correct missplicing in neurogenetic diseases.
    Siva K; Covello G; Denti MA
    Nucleic Acid Ther; 2014 Feb; 24(1):69-86. PubMed ID: 24506781
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Skipping multiple exons of dystrophin transcripts using cocktail antisense oligonucleotides.
    Echigoya Y; Yokota T
    Nucleic Acid Ther; 2014 Feb; 24(1):57-68. PubMed ID: 24380394
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Potential therapeutic applications of antisense morpholino oligonucleotides in modulation of splicing in primary immunodeficiency diseases.
    Du L; Gatti RA
    J Immunol Methods; 2011 Feb; 365(1-2):1-7. PubMed ID: 21147113
    [TBL] [Abstract][Full Text] [Related]  

  • 5. New approaches to the treatment of orphan genetic disorders: Mitigating molecular pathologies using chemicals.
    Velho RV; Sperb-Ludwig F; Schwartz IV
    An Acad Bras Cienc; 2015 Aug; 87(2 Suppl):1375-88. PubMed ID: 26247150
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antisense Oligonucleotide Therapy for Inherited Retinal Dystrophies.
    Gerard X; Garanto A; Rozet JM; Collin RW
    Adv Exp Med Biol; 2016; 854():517-24. PubMed ID: 26427454
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Peptide conjugation of 2'-O-methyl phosphorothioate antisense oligonucleotides enhances cardiac uptake and exon skipping in mdx mice.
    Jirka SM; Heemskerk H; Tanganyika-de Winter CL; Muilwijk D; Pang KH; de Visser PC; Janson A; Karnaoukh TG; Vermue R; 't Hoen PA; van Deutekom JC; Aguilera B; Aartsma-Rus A
    Nucleic Acid Ther; 2014 Feb; 24(1):25-36. PubMed ID: 24320790
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Making antisense of splicing.
    Garcia-Blanco MA
    Curr Opin Mol Ther; 2005 Oct; 7(5):476-82. PubMed ID: 16248283
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antisense oligonucleotide treatment for a pseudoexon-generating mutation in the NPC1 gene causing Niemann-Pick type C disease.
    Rodríguez-Pascau L; Coll MJ; Vilageliu L; Grinberg D
    Hum Mutat; 2009 Nov; 30(11):E993-E1001. PubMed ID: 19718781
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Overview on applications of antisense-mediated exon skipping.
    van Roon-Mom WM; Aartsma-Rus A
    Methods Mol Biol; 2012; 867():79-96. PubMed ID: 22454056
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Gene correction of a duchenne muscular dystrophy mutation by meganuclease-enhanced exon knock-in.
    Popplewell L; Koo T; Leclerc X; Duclert A; Mamchaoui K; Gouble A; Mouly V; Voit T; Pâques F; Cédrone F; Isman O; Yáñez-Muñoz RJ; Dickson G
    Hum Gene Ther; 2013 Jul; 24(7):692-701. PubMed ID: 23790397
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Correction of prototypic ATM splicing mutations and aberrant ATM function with antisense morpholino oligonucleotides.
    Du L; Pollard JM; Gatti RA
    Proc Natl Acad Sci U S A; 2007 Apr; 104(14):6007-12. PubMed ID: 17389389
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Splicing in the immune system: potential targets for therapeutic intervention by antisense-mediated alternative splicing.
    Mourich DV; Iversen PL
    Curr Opin Mol Ther; 2009 Apr; 11(2):124-32. PubMed ID: 19330718
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An update on gain-of-function mutations in primary immunodeficiency diseases.
    Jhamnani RD; Rosenzweig SD
    Curr Opin Allergy Clin Immunol; 2017 Dec; 17(6):391-397. PubMed ID: 29040208
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Modern management of primary T-cell immunodeficiencies.
    Pachlopnik Schmid J; Güngör T; Seger R
    Pediatr Allergy Immunol; 2014 Jun; 25(4):300-13. PubMed ID: 24383740
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Progress and prospects: targeted gene alteration (TGA).
    Parekh-Olmedo H; Kmiec EB
    Gene Ther; 2007 Dec; 14(24):1675-80. PubMed ID: 17972921
    [TBL] [Abstract][Full Text] [Related]  

  • 17. New developments in exon skipping and splice modulation therapies for neuromuscular diseases.
    Touznik A; Lee JJ; Yokota T
    Expert Opin Biol Ther; 2014 Jun; 14(6):809-19. PubMed ID: 24620745
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Enhancement of premature stop codon readthrough in the CFTR gene by Ataluren (PTC124) derivatives.
    Pibiri I; Lentini L; Melfi R; Gallucci G; Pace A; Spinello A; Barone G; Di Leonardo A
    Eur J Med Chem; 2015 Aug; 101():236-44. PubMed ID: 26142488
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dystrophin expression in the mdx mouse after localised and systemic administration of a morpholino antisense oligonucleotide.
    Fletcher S; Honeyman K; Fall AM; Harding PL; Johnsen RD; Wilton SD
    J Gene Med; 2006 Feb; 8(2):207-16. PubMed ID: 16285002
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Target selection for antisense oligonucleotide induced exon skipping in the dystrophin gene.
    Errington SJ; Mann CJ; Fletcher S; Wilton SD
    J Gene Med; 2003 Jun; 5(6):518-27. PubMed ID: 12797117
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.